Scopus Eşleşmesi Bulundu
8
Atıf
15
Cilt
🔓
Açık Erişim
Scopus Yazarları: Akin Çalişir, Fatih Turkoglu, Bahadır Öztürk
Özet
There is limited data on the relationship of miRNAs with parameters that may affect surgical management or reflect tumour prognosis. It was aimed to evaluate serum miRNA levels in breast carcinoma cases and reveal the relationship between these levels and prognosis-related factors such as the histological type of the tumour, estrogen receptor, progesterone receptor, Ki-67 index, HER-2neu, E-cadherin, tumour size, CK5/6, CA15.3 levels, number of tumour foci, number of metastatic lymph nodes, and status of receiving neoadjuvant therapy. Thirty-five patients with a histopathologically confirmed breast carcinoma diagnosis in the case group and 35 healthy individuals in the control group were examined. miR-206, miR-17-5p, miR-125a, miR-125b, miR-200a, Let-7a, miR-34a, miR-31, miR-21, miR-155, miR-10b, miR-373, miR-520c, miR-210, miR-145, miR-139-5p, miR-195, miR-99a, miR-497 and miR-205 expression levels in the serum of participants were determined using the Polymerase Chain Reaction method. While serum miR-125b and Let-7a expression levels were significantly higher in breast cancer patients, miR-17-5p, miR-125a, miR-200a, miR-34a, miR-21, miR-99a and miR-497 levels were significantly lower in them. The Let-7a expression level had a statistically significant relationship with breast cancer histological type and HER-2neu parameters, miR-17-5p, miR-125b, Let-7a, miR-34a, miR-21 and miR-99a levels with E-cadherin, miR-34a, miR-99a and miR-497 with CA15.3, miR-125b, miR-200a and miR-34a with the number of metastatic lymph nodes, miR-125a with the number of tumour foci and miR-200a with the status of having the neoadjuvant therapy. Serum miR-17-5p, miR-125a, miR-125b, miR-200a, Let-7a, miR-34a, miR-21, miR-99a and miR-497 expression levels were determined to have predictive and prognostic importance in breast cancer.
Anahtar Kelimeler (Scopus)
Biomarker
Breast cancer
Microrna
Prognosis
Scimago Dergi Bilgisi
Otomatik ISSN Eşleştirmesi
2024 yılı verileri
Discover Oncology
Q2
SJR Quartile
0,880
SJR Skoru
47
H-Index
🔓
Açık Erişim
Kategoriler: Endocrine and Autonomic Systems (Q2) · Endocrinology (Q2) · Endocrinology, Diabetes and Metabolism (Q2) · Oncology (Q2) · Cancer Research (Q3)
Alanlar: Biochemistry, Genetics and Molecular Biology · Medicine · Neuroscience
Ülke: Germany
· Springer Science and Business Media Deutschland GmbH
Bu bilgiler makale yılına göre Scimago veritabanından ISSN eşleştirmesiyle otomatik getirilmektedir.
Dergi sıralama verileri Scimago'nun ilgili yılı baz alınmaktadır.
Anahtar Kelimeler
"Breast cancer"
"Microrna"
"Prognosis"
"Biomarker"
Biomarker
Breast cancer
Microrna
Prognosis
mavi = YÖKSİS
yeşil = Scopus
Makale Bilgileri
Dergi
DISCOVER ONCOLOGY
ISSN
2730-6011
Yıl
2024
/ 1. ay
Cilt / Sayı
15
/ 1
Makale Türü
Özgün Makale
Hakemlik
Hakemli
Endeks
SCI
TEŞV Puanı
27,00
Yayın Dili
Türkçe
Kapsam
Uluslararası
Toplam Yazar
3 kişi
Erişim Türü
Basılı
Alan
Sağlık Bilimleri Temel Alanı
Genel Cerrahi
"Breast cancer","Microrna","Prognosis","Biomarker"
YÖKSİS Yazar Kaydı
Yazar Adı
ÖZTÜRK BAHADIR,ÇALIŞIR AKIN,TÜRKOĞLU FATİH
YÖKSİS ID
9500720
Hızlı Erişim
Metrikler
Scopus Atıf
8
TEŞV Puanı
27,00
Yazar Sayısı
3